NAD(P)H oxidase in the failing human heart  by Krijnen, P.A.J. et al.
In the absence of a proven IV preparation, the proposal by
Huxtable et al. for the use of saline hydration and oral NAC seems
eminently sensible although, as they point out, evidence for the
effectiveness of oral NAC when given immediately prior to
contrast exposure is limited. A variety of other maneuvers may also
reduce the incidence of RCIN, and we would suggest the following
be included in any protocol:
1. The use of iso-osmolar contrast agents (2).
2. Minimization of the radiocontrast dose employed (3) (e.g.,
biplane imaging and echocardiography in place of contrast
ventriculography).
3. Maximum 4-h fast prior to contrast exposure to prevent salt and
water depletion.
4. Cessation of potentially nephrotoxic drugs prior to contrast
exposure and reinstitution when renal function has been shown
to be stable.
5. Assessment of renal function three days’ postprocedure.
We believe that awareness of RCIN will do much to reduce its
impact.
The suggestion of a third arm to the study to compare oral and
IV NAC is an interesting one. However, this was discounted
during the design stage of our trial owing to the low incidence of
RCIN in patients treated with oral NAC (approximately 2% [4]).
The estimated number of patients required to show a difference or
to prove equivalence between treatments would thus have been
prohibitively large.
Finally, we emphasize that our study did not include emergency
patients, as this would not have allowed randomization to the
slower hydration arm of the protocol.
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NAD(P)H Oxidase in
the Failing Human Heart
With great interest we read the recent JACC editorial comment by
Warnholtz and Munzel (1) in which they emphasize the impor-
tance of NAD(P)H-derived reactive oxygen species in heart
failure. This comment was for the greater part inspired by the
interesting study by Heymes et al. (2) published in the same issue
of JACC, which shows by immunohistochemistry that gp91phox is
expressed in human cardiomyocytes.
In their editorial comment, Warnholtz and Munzel state that
Heymes et al. (2) for the first time provide evidence of the activation
and expression of the NAD(P)H oxidase in human cardiomyocytes.
However, in March 2003 we already published a study in which we
provided evidence for the expression of gp91phox (Nox2) in human
cardiomyocytes (3). This was proven not only by immunohistochem-
istry but also by Western blot analysis on isolated human cardiomyo-
cytes instead of total-tissue homogenates.
Although both studies describe the expression of Nox2 in
human cardiomyocytes, there are some differences. For example,
Heymes et al. (2) show by Western blot on total-tissue homoge-
nates that there is no difference in Nox2 expression between failing
and nonfailing hearts, whereas we demonstrated by immunohisto-
chemistry that the number of Nox2-expressing cardiomyocytes within
the infarction area is significantly increased after acute myocardial
infarction (AMI). We have to keep in mind, however, that with AMI
we have studied an acute phenomenon, whereas congestive heart
failure (CHF) is a more or less chronic process. This might explain the
interesting differences in the pattern of Nox2 expression between
acute and chronic heart disease and could point to a different
regulation of Nox2 expression in both phenomena.
The data of Heymes et al. (2) therefore, corroborate our own
findings in that we both, using different antibodies, show that
Nox2 is expressed in human cardiomyocytes. Their measured
increase in NAD(P)H oxidase activity after CHF and our in-
creased Nox2 expression after AMI emphasize the role of the
NAD(P)H oxidase(s) in human cardiovascular pathophysiology.
We completely agree with Warnholtz and Munzel that the
possible co-expression of other Nox isoforms, the functional
contribution of the cardiomyocyte-specific oxidases to the ROS-
mediated effects observed in cardiac tissue homogenates, and the
search for possibilities of pharmacological intervention are impor-
tant issues that need to be addressed now.
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In our recent editorial (1) we commented on the expression and
activity of the NAD(P)H oxidase subunit gp91phox isoform in the
failing human heart reported by Heymes et al. (2). We also stated
that this evidence was provided for the first time, not mentioning
the article by Krijnen et al. (3), which was published in the March
issue of the Journal of Clinical Pathology. One simple reason for that
was that our editorial comment was already in press when the
report from Krijnen et al. appeared. In that study the investigators
describe the existence of Nox 2 (gp91phox) in normal human
cardiomyocytes and an up-regulation of the expression as assessed
by Western blotting technique and by immunohistochemistry in
viable and jeopardized cardiomyocytes of freshly infarcted areas.
Since this report was published in March, we agree that the study
was indeed the first to comment on the expression of the
NAD(P)H oxidase subunit Nox2 in human cardiomyocytes. Al-
though the researchers have observed an increase in Nox2 in
myocardial areas subject to acute myocardial infarction (AMI), one
cannot really compare this situation with that of chronic congestive
heart failure. Acute myocardial infarction is always accompanied
by an acute and severe inflammatory response, and in the studies by
Krijnen et al. no data were provided as to whether these patients
had clinical signs of acute heart failure. Thus, the correspondent
may agree that Heymes et al. (2) provided the first evidence for a
lack of changes in the expression of Nox2 but an increase in the
activity of the enzyme in patients with severe chronic congestive
heart failure.
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We thank Dr. Krijnen and colleagues for their interest in our
report (1). The data, presented at the American Heart Association
scientific sessions in 2002 (2), build upon prior experimental
studies from our group and others (see Ref. 1). Although Krijnen
et al. (3) discuss some parallels between our study and their recent
interesting publication, several important differences should be
emphasized.
The NAD(P)H oxidase is a multisubunit complex that requires
not only a core catalytic Nox subunit but also several other
components (p22phox, p47phox, p40phox, rac) for its function (4).
Clear evidence of NAD(P)H oxidase expression and activity
requires both the demonstration of multiple subunits and evidence
of biochemical activity, as provided in our report (1). In addition,
analysis of expression based solely on immunoblotting or immu-
nohistochemistry is complicated by the fact that several Nox
isoforms have recently been reported (4). Ideally, antibody-based
methods should be complemented by RNA-based analyses (1).
The best approach in experimental studies may be to employ
gene-modified models (5).
With respect to NAD(P)H oxidase activation, this is recognized
to occur through posttranslational modifications of one or more
subunits (e.g., phosphorylation of p47phox) and/or altered expres-
sion levels (4). In our opinion, comments on mechanisms of
activation of this complex enzyme based solely on qualitative
analyses of Nox2 by immunohistochemistry are probably unwar-
ranted. Our study found no change in overall tissue expression level
of the four main oxidase subunits in end-stage chronic heart
failure, whereas immunofluorescence studies indicated a translo-
cation of p47phox to the cardiomyocyte sarcolemma where
gp91phox was also present (1). Nevertheless, activation mechanisms
of the oxidase remain speculative.
Finally, the condition we studied (chronic nonischemic conges-
tive heart failure) (1) is quite distinct from the focus of Krijnen’s
report (acute myocardial infarction) (3). The NADPH oxidase
subunit expression, cellular localization, stimuli for activation, and
activation mechanisms could well be significantly different among
these conditions.
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